

In the claims:

Claims 1-6 (Canceled)

7. **(Currently amended)** A method for treating or reducing the advancement, severity or effects of neoplasia comprising ~~the step of~~ administering a therapeutically effective amount of at least two compositions, each composition comprising at least one LT- β -R activating agent ~~agents~~ and a pharmaceutically acceptable carrier, wherein at least one LT- β -R activating agent comprises an anti-LT- β -R antibody.
8. **(Original)** The method according to claim 7, wherein the anti-LT-B-R antibody is CBE11.
9. **(Previously presented)** The method according to claim 7, comprising at least two anti-LT- β -R monoclonal antibodies which are directed against non-overlapping epitopes of LT- β -R.
10. **(Original)** The method according to claim 9, wherein one anti-LT- β -R monoclonal antibody is selected from the group consisting of AGH1 and BDA8, and another anti-LT- β -R monoclonal antibody is selected from the group consisting of BCG6, BHA10, BKA11, CDH10 and CBE11.
11. **(Original)** The method according to claim 9, wherein one anti-LT- β -R monoclonal antibody is selected from the group consisting of BCG6 and BHA10, and another anti-LT- β -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BKA1 1, CDH10, and CBE11.
12. **(Original)** The method according to claim 9, wherein one anti-LT- β -R monoclonal antibody is selected from the group consisting of BKA1 1 and CDH10, and another anti-LT- β -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BCG6, BHA10, and CBE11.
13. **(Original)** The method according to claim 9, wherein one anti-LT- β -R monoclonal antibody is CBE11, and another anti-LT- β -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BCG6, BHA10, BKA11, CDH10 and CBE11.

14. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT- β -R monoclonal antibody is CBE11 and at least one anti-LT- β -R monoclonal antibody is BHA10.

15. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT- β -R monoclonal antibody is CBE11 and at least one anti-LT- β -R monoclonal antibody is CDH10.

16. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT- β -R monoclonal antibody is AGH1 and at least one anti-LT- β -R monoclonal antibody is CDH10.

17. **(Currently amended)** The method according to claim 7 ~~any one of claims 6-16~~, further comprising IFN- γ .

Claims 18-37 **(Canceled)**

38. **(Previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of at least two LT- β -R activating agents, and a pharmaceutically acceptable carrier, wherein at least one LT- β -R activating agent comprises an anti-LT- β -R antibody.

39. **(Original)** The pharmaceutical composition according to claim 38, wherein the anti-LT- β -R antibody is a monoclonal antibody.

40. **(Original)** The pharmaceutical composition according to claim 39, wherein the anti-LT- β -R antibody is CBE11.

41. **(Currently amended)** The pharmaceutical composition according to claim ~~38~~ 37, wherein at least two LT- β -R activating agents comprise anti-LT- β -R monoclonal antibodies which are directed against non-overlapping epitopes of LT- β -R.

42. **(Original)** The pharmaceutical composition according to claim 41, wherein one anti-LT- β -R monoclonal antibody is selected from the group consisting of AGH1 and BDA8, and

another anti-LT- β -R monoclonal antibody is selected from the group consisting of BCG6, BHA10, BKA11, CDH10 and CBE11.

43. **(Original)** The pharmaceutical composition according to claim 41, wherein one anti-LT- β -R monoclonal antibody is selected from the group consisting of BCG6 and BHA10, and another anti-LT- β -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, CKA11, CDH10 and CBE11

44. **(Original)** The pharmaceutical composition according to claim 41, wherein one anti-LT-B-R monoclonal antibody is selected from the group consisting of BKA11 and CDH10, and another anti-LT-B-R monoclonal antibody is selected from the group consisting of AGH1 and BDA8, BCG6, BHA10 and CBE11.

45. **(Original)** The pharmaceutical composition according to claim 41, wherein the anti-LT- β -R monoclonal antibody is CBE11, and another anti-LT- β -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BCG6, BHA10, BKA11, CDH10, and CBE11.

46. **(Previously presented)** The pharmaceutical composition according to claim 41, wherein at least one anti-LT- β -R monoclonal antibody is CBE11 and at least one anti-LT-B-R monoclonal antibody is BHA10.

47. **(Previously presented)** The pharmaceutical composition according to claim 41, wherein at least one anti-LT-B-R monoclonal antibody is CBE11 and at least one anti-LT-B-R monoclonal is CDH10.

48. **(Previously presented)** The pharmaceutical composition according to claim 41, wherein at least one anti-LT-B-R monoclonal antibody is AGH1 and at least one anti-LT- β -R monoclonal antibody is CDH10.

49. **(Previously presented)** The pharmaceutical composition according to any one of the claims 41-48, further comprising IFN- γ .

Claims 50-60 **(Canceled)**

61. **(Previously presented)** The method according to claim 7, wherein the anti- LT-B-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

62. **(Previously presented)** The method according to claim 7, wherein the anti-LT- β -R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB 11795.

63. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT-B-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB 11793

64. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT- β -R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB 11795.

65. **(Previously presented)** The method according to claim 64, further comprising at least one anti- LT- β -R antibody having the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

66. **(Previously presented)** The pharmaceutical composition according to claim 38, wherein the anti- LT-B-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

67. **(Previously presented)** The pharmaceutical composition according to claim 38, wherein the anti- LT-B-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

68. **(Previously presented)** The pharmaceutical composition according to claim 46, wherein at least one anti-LT-B-R antibody has the same epitope specificity as an antibody produced by cell line CBE11.1, ATCC accession number HB11793.

69. **(Previously presented)** The pharmaceutical composition according to claim 46, wherein at least one anti-LT-B-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.
70. **(Previously presented)** The pharmaceutical composition according to claim 69, further comprising at least one anti-LT-B-R antibody having the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.
71. **(New)** The method according to claim 7, wherein the anti-LT- β -R antibody comprises CDRs from antibody CBE11 produced by hybridoma CB.E11.1 (ATCC Accession No. HB11793).
72. **(New)** The method according to claim 7, wherein the anti-LT- β -R antibody is selected from the group consisting of CBE11 produced by hybridoma CB.E11.1 (ATCC Accession No. HB11793), BKA11 produced by hybridoma BK.A11.AC10 (ATCC Accession No. HB11799), CDH10 produced by hybridoma CD.H10.1 (ATCC Accession No. HB11797), BCG6 produced by hybridoma BC.G6.AF5 (ATCC Accession No. HB11794), BHA10 produced by hybridoma BH.A10 (ATCC Accession No. HB11795), and AGH1 produced by hybridoma AG.H1.5.1 (ATCC Accession No. HB11796).
73. **(New)** The method according to claim 7, wherein the anti-LT- β -R antibody is a F(ab)₂.
74. **(New)** The method according to any one of claims 7, 61-65, 71, and 73, wherein the anti-LT- β -R antibody is a chimeric antibody.
75. **(New)** The method according to any one of claims 7, 61-65, 71, and 73, wherein the anti-LT- β -R antibody is a humanized antibody.
76. **(New)** The method according to any one of claims 7, 61-65, 71, and 73-75, further comprising an anti-tumor therapy.

77. (New) The method according to claim 76, wherein the anti-tumor therapy is radiation or chemotherapy.

78. (New) The method according to any one of claims 7, 61-65, 71, and 73-75, wherein the second agent is selected from the group consisting of IFN- α , TNF, and an anti-LT- β -R antibody.

79. (New) The pharmaceutical composition according to any one of claims 38, 39, and 66-70, wherein the anti-LT- β -R antibody is a chimeric antibody.

80. (New) The pharmaceutical composition according to any one of claims 38, 39, and 66-70, wherein the anti-LT- β -R antibody is a humanized antibody.

81. (New) The pharmaceutical composition according to any one of claims 38, 39, and 66-70, wherein the anti-LT- β -R antibody is a F(ab)₂.

82. (New) A method for treating or reducing the advancement, severity or effects of neoplasia comprising administering an effective amount of a pharmaceutical composition comprising an anti-LT- β -R antibody and a pharmaceutically acceptable carrier, wherein the composition is administered in the presence of an exogenous LT- β -R activating agent.

83. (New) The method according to claim 82, wherein the anti-LT-B-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

84. (New) The method according to claim 82, wherein the anti-LT- β -R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB 11795.

85. (New) The method according to claim 82, wherein the anti-LT- β -R antibody comprises CDRs from antibody CBE11 produced by hybridoma CB.E11.1, ATCC Accession No. HB11793.

86. **(New)** The method according claim 82, wherein the anti-LT- β -R antibody is selected from the group consisting of CBE11 produced by hybridoma CB.E11.1 (ATCC Accession No. HB11793), BKA11 produced by hybridoma BK.A11.AC10 (ATCC Accession No. HB11799), CDH10 produced by hybridoma CD.H10.1 (ATCC Accession No. HB11797), BCG6 produced by hybridoma BC.G6.AF5 (ATCC Accession No. HB11794), BHA10 produced by hybridoma BH.A10 (ATCC Accession No. HB11795), and AGH1 produced by hybridoma AG.H1.5.1 (ATCC Accession No. HB11796).
87. **(New)** The method according to any one of claims 82-86, wherein the anti-LT- β -R antibody is a F(ab)2.
88. **(New)** The method according to any one of claims 82-86, wherein the anti-LT- β -R antibody is a chimeric antibody.
89. **(New)** The method according to any one of claims 82-86, wherein the anti-LT- β -R antibody is a humanized antibody.
90. **(New)** The method according to any one of claims 82-86, wherein the LT- β -R activating agent is selected from the group consisting of IFN- α , TNF, and an anti-LT- β -R antibody.
91. **(New)** The method according to any one of claims 82-86, further comprising an anti-tumor therapy.
92. **(New)** The method according to claim 91, wherein the anti-tumor therapy is radiation or chemotherapy.